2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-116422
    N,N-Dimethyl sphinganine 17267-46-8 98%
    N,N-Dimethyl sphinganine is an ester product.
    N,N-Dimethyl sphinganine
  • HY-116503
    Methyl 3-hydroxytridecanoate 150024-70-7 98%
    Methyl 3-hydroxytridecanoate (3-Hydroxy tridecanoic acid methyl ester) is an ester product.
    Methyl 3-hydroxytridecanoate
  • HY-116508
    MK 319 1462383-00-1 98%
    MK 319 is a selective aldose reductase (AR) inhibitor with an IC50 of 0.3 μM. MK 319 can be utilized in diabetes research.
    MK 319
  • HY-116576
    LY219057 150351-93-2 98%
    LY219057 is a potent antagonist of cholecystokinin octapeptide (CCK-8), with the ID50 of 287.5 nM.
    LY219057
  • HY-116600
    AL-4114 139911-05-0 98%
    AL-4114 is an aldose reductase inhibitor which can be utilized in research related to the prevention of diabetic cataractogenesis.
    AL-4114
  • HY-116661
    Cannabigerovarin 55824-11-8 98%
    Cannabigerovarin (CRM) (Item No. 29117) is a certified reference material categorized as a phytocannabinoid.1 This product is intended for research and forensic applications.
    Cannabigerovarin
  • HY-116666
    Etomidate acid 56649-48-0 98%
    Etomidate acid is an Etomidate analog. Etomidate acid inhibits the binding of metyrapone (Metyrapol) and 4-iodometomidate to rat adrenal membrane sites.
    Etomidate acid
  • HY-116682
    GKA-71 863504-35-2 98%
    GKA-71 is an orally active Glucokinase activator, possesses an islet protective effect.
    GKA-71
  • HY-116703
    L-erythro-Dihydrosphingosine 6036-76-6 98%
    L-erythro-Dihydrosphingosine is an ester product.
    L-erythro-Dihydrosphingosine
  • HY-116752
    Dinor-12-oxo phytodienoic acid 197247-23-7 98%
    Dinor-12-oxo phytodienoic acid (2,3-Dinor-12-oxo-10,15(Z)-phytodienoic acid) is an ester product.
    Dinor-12-oxo phytodienoic acid
  • HY-116959
    SM-130686 259667-25-9 98%
    SM-130686 is an oxindole derivative and an active GH secretagogue (GHS). SM-130686 stimulates GH release with a Half-maximum stimulation of 6.3 nM. SM-130686 has an orally active.
    SM-130686
  • HY-117044
    12(R)-HEPE 109430-12-8 98%
    12(R)-HEPE is a monohydroxy fatty acid synthesized from EPA by the eggs of the sea urchin, S. purpuratus.1 The biological activity of 12(R)-HEPE has not been extensively documented, but may be similar to that of 12(R)-HETE.
    12(R)-HEPE
  • HY-117057
    Hexaenoic acid 105528-06-1 98%
    Very long chain polyunsaturated fatty acids (VLCPUFAs) are important components of ceramides and sphingomyelin and are present in retina, sperm, and brain. Tetratriaconta-16(Z),19(Z),22(Z),25(Z),28(Z),31(Z)-hexaenoic acid is a C34:6 VLCPUFA whose specific biological actions are largely unknown. This VLCPUFA, along with others, has been investigated for its role in activating protein kinase C.
    Hexaenoic acid
  • HY-117110
    Arginylproline 2418-69-1 98%
    Arginylproline (H-Arg-Pro-OH) is a dipeptide consisted of arginine and proline. Arginylproline reduces intracellular triglyceride (TG) levels stimulated by Oleic acid (HY-N1446), through the peptide transporter 1 (PepT1) pathway.
    Arginylproline
  • HY-117131
    ZINC17167211 592539-21-4 98%
    ZINC17167211 is a potent PPAR-α agonist (EC50=0.16 nM) that can be used in the study of diabetes, hyperlipidemia, and inflammatory diseases.
    ZINC17167211
  • HY-117219
    SKF 104976 136209-43-3 98%
    SKF 104976 is a 3,2-carboxylic acid derivative with potent 14-alpha-demethylase (14 alpha DM) inhibitory activity. SKF 104976 inhibited 14 alpha DM activity by 50% at 2 nM in Hep G2 cell extracts. SKF 104976 inhibited the incorporation of [14C]acetate into cholesterol in intact cells at similar concentrations, accompanied by accumulation of lanosterol, and resulted in a 40-70% decrease in 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) activity. SKF 104976 did not affect the uptake and degradation of low-density lipoprotein in Hep G2 cells, indicating that HMGR and low-density lipoprotein receptor activities are not coordinately regulated under these conditions. The inhibitory effect of SKF 104976 on HMGR activity remained unchanged even when the flux of carbon units in the sterol synthesis pathway was reduced by 80%. SKF 104976 did not inhibit HMGR activity under conditions where sterol synthesis was almost completely blocked by lovastatin.
    SKF 104976
  • HY-117431
    Prostaglandin B3 36614-32-1 98%
    Prostaglandin B3 (PGB3) is a member of the class of prostaglandins B and a secondary alcohol. PGB3 exhibits a rather low affinity to human PPARγ with a Ki value greater than 1 mM compared with Ki values of 26.28 ± 8.7 μM for PGB1 and 77 ± 37.7 μM for PGB2.
    Prostaglandin B3
  • HY-117446
    AS-1669058 1395553-32-8 98%
    AS-1669058 is a GPR119 agonist and a potential inhibitor of type 2 diabetes. AS-1669058 induces insulin secretion in response to high blood glucose levels in vitro and in vivo and increases insulin promoter activity. In animal studies, AS-1669058 improved glucose tolerance and reduced blood glucose levels in db/db mice.
    AS-1669058
  • HY-117466
    FR186054 179053-90-8 98%
    FR186054 is an oral active acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor with the IC50 of 99 nM. FR186054 shows hypocholesterolemic effect and can be used for study of hypercholesterolemia and atherosclerosis.
    FR186054
  • HY-117562
    a-FABP-IN-1 1310361-52-4 98%
    a-FABP-IN-1 (Compound 5g) is a potent and selective human adipocyte fatty acid-binding protein (a-FABP) inhibitor with a Ki below 1.0 nM. a-FABP-IN-1 inhibits the pro-inflammatory cytokine production.
    a-FABP-IN-1
Cat. No. Product Name / Synonyms Application Reactivity